Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Symonds

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 7